Figure 1.
PASI scores (A) and CRP levels (B) at different time points after the treatment with IL-23 (guselkumab) or IL-17 (secukinumab and ixekizumab) inhibitor. * p < 0.05 versus week 0 for each group; ** p < 0.001 versus week 0 for each group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.